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Clinical Investigation
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Sensitive Areas of the Face: A Report of Clinical
Outcomes and Acute and Subacute Toxicities
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Purpose: Basal cell and cutaneous squamous cell carcinoma are common malignancies (keratinocyte carcinomas [KCs]). Surgical
resection is the standard of care. Radiation using high-dose rate brachytherapy (HDR-BT) may serve as a superior alternative where surgical
scars may be of cosmetic concern or in elderly patients with signiﬁcant comorbidity. We aim to describe the clinical and cosmetic outcomes
as well as posttreatment radiation toxicities associated with HDR-BT in patients who were treated for KCs of the face.
Methods and Materials: Patients with KCs treated with HDR-BT from 2015 to 2018 were included in the study. Patient medical records
and clinical photos were reviewed at multiple time points: start of treatment, end of treatment, short-term (2 week) follow-up, 3-month
follow-up, and if needed at 6 months. Radiation toxicity was graded using the Radiation Therapy Oncology Grading (RTOG) acute
toxicity scale. Median (range) toxicity grades at follow-up intervals were calculated. Clinical outcomes including local recurrence were
evaluated for all patients.
Results: The study included 19 patients and 20 KCs. The median radiation dose was 42 Gy (39-42 Gy) over 6 fractions. The median
toxicity at completion of treatment was RTOG grade 2 (85% of patients). At short-term follow-up, 50% of patients (n Z 10) improved
to RTOG grade 1 (0-2). At 3 months, 70% of patients (n Z 14) had RTOG grade 0, and by 6 months, 100% of patients (n Z 18) had
RTOG grade 0. No RTOG grade 3 or higher skin toxicity was observed. With a median follow-up of 7.2 months (range, 1.3-54.4
months), the local recurrence-free survival was 95%.
Conclusions: We demonstrate that HDR-BT can be used as deﬁnitive treatment of KCs of the face with excellent cosmetic outcomes and local
control. Acute and subacute skin toxicities were most commonly RTOG grade 2 or less with resolution of patient’s skin toxicity by 3 months.
Ó 2020 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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2

J.M. Taylor et al

Introduction
Skin cancers, including basal cell carcinoma (BCC)
and cutaneous squamous cell carcinoma (SCC), are the
most common human malignancies and combined account for approximately 5.4 million new cases annually in
the United States.1,2 Although BCC and SCC, also known
as keratinocyte carcinomas (KCs), have low metastatic
potential and mortality rates compared with other malignancies, they can be locally invasive and destructive and
have deleterious effects on quality of life (QOL) if left
untreated.3,4 The standard of care for KC is a diagnostic
biopsy followed by surgery with excision or Mohs micrographic surgery. Although surgery is considered the
deﬁnitive treatment by many due to low local recurrence
of <5%, it has limitations, such as being invasive and
costly, projected at 8 billion dollars annually.5-7 Overall,
in the United States, treatment for skin cancers grew by
>50% from 1996 to 2008, but the use of Mohs micrographic surgery increased by 400% over this approximate
same period.8 However, in functionally limiting or sensitive cosmetic sites including the tip of the nose, ear,
ﬁnger knuckles, or large tumors on the scalp, surgery can
introduce morbidities, including nerve damage, movement limiting scars, or less desirable cosmetic outcomes.9,10 Moreover, given the aging population, many
patients who will require treatment for KCs are elderly
with multiple medical comorbidities, including venous
insufﬁciency, compromised blood circulation, and aging
skin, all of which can contribute to slow or nonhealing
surgical wounds, and thus a noninvasive approach in this
patient population may be ideal.11-13 Finally, in addition
to limitations caused by cosmetically limiting sites and
aging patients, cases involving markedly larger areas of
the face, patients who are poor surgical candidates, recurrences after previous surgical attempts, or patient’s
wishes to avoid any line of scar, other treatment alternatives to surgery exist and should be discussed with patients in selecting an optimal treatment strategy.
Speciﬁcally, radiation treatment using high-dose rate
brachytherapy (HDR-BT) has become increasingly used
over the past decade for the treatment of early-stage KC,
with high local control rates with series reporting local
control between 90% to 98% and good-excellent cosmetic
outcomes.14-18 HDR-BT is a growing treatment option for
KC due to its less invasive nature and higher tolerability
proﬁle in elderly patients who may not tolerate the
required time on the operating table or whose comorbidities will contribute to poor wound healing and
diminished cosmetic outcome. In addition to excellent
local control, HDR-BT also has an appealing cosmetic
outcome, with some series reporting excellent cosmetic
outcomes in 98% of patients treated.14,16,17 Traditional
radiation using daily external beam radiation therapy
(EBRT) takes between 3 to 6 weeks, with patients
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receiving between 15 to 20 fractions. There are alternative
EBRT fractionation schedules that use hypofractionation,
including a 5-fraction course that is supported by the
National Comprehensive Cancer Center Network guidelines for KCs <20 mm in size.19 However, in clinical
practice, this fractionation is generally limited to small
lesions <5 mm in size, and a 5 fraction schedule is not
supported by guidelines from the American Society of
Radiation Oncology.20 For small facial KCs, HDR-BT
allows for an expedited treatment timeline and greater
patient convenience, with deﬁnitive treatment in 6 to 7
fractions, and it can be used in lesions >5 mm.
In this study, we aimed to describe the clinical outcomes and posttreatment radiation toxicity associated
with HDR-BT in patients treated for KCs of the face at
our institution as well as our procedure for prescribing
and using HDR-BT in our clinic. We believe this will
provide valuable information for patients, caregivers, and
clinicians when discussing possible treatment options and
outcomes regarding facial KCs in patients unable to have
surgery or who are seeking alternative approaches.

Methods and Materials
After institutional review board approval, consecutive
patients treated with HDR-BT at our institution with
pathologically conﬁrmed KC, primarily of the nose, lip,
or scalp, were included in the current study.

Procedure details and radiation prescription
All lesions for selected cases were limited to a
maximum depth of 4 mm and a diameter equal to or less
than 25 mm. The depth of invasion was assessed by both
a radiation oncologist and dermatologist. In scenarios
where there were signiﬁcant concerns about depth of invasion, ultrasound or computed tomography was used to
determine depth. The maximal diameter of 25 mm is a
limitation of the Leipzig skin applicator and reﬂects the
largest diameter used in our clinic. All patients were
immobilized with thermoplastic cranial masks with face
and nose exposed. The gross tumor volume was assessed
visually and outlined by the treating physician. The
planning target volume consisted of the gross tumor
volume with a 3-mm margin and was outlined on the
surface of the skin with a marker pen. Appropriately sized
Leipzig applicators were chosen based on the planning
target volume size. All patients were treated with the
Leipzig skin applicator (Nucletron, Elekta AB, Stockholm, Sweden). Immobilization of the applicator was
achieved using a department manufactured articulated
arm device (Figs 1 and 2). All treatments were delivered
under the direct supervision of the radiation oncologist, an
authorized user, for accurate applicator positioning and
the authorized medical physicist. The treatment dose was
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Figure 1
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Leipzig applicator set. Images courtesy of Elekta.

prescribed to a depth of 3 mm or less. The prescription
dose was 42 Gy in 6 or 7 fractions, delivered 2 to 3 times
per week, with a minimum interval of 48 hours between
fractions and not exceeding 3 weeks.

Toxicity assessment
Patient notes and treatment images were collected
retrospectively for all patients to determine type of KC,
follow-up dates, and grading for toxicity at the lesion site.
Patient images were examined at 4-time points for all
patients (5-time points for some) including (1) at the start
of treatment, (2) end of treatment, (3) short-term (2-week)
follow-up, and (4) 3-month follow-up. Therefore, all patients had images reviewed a minimum of 4 times. Sixmonth follow-up pictures were taken for patients who had
any unresolved skin toxicities at the 3-month follow-up.
However, all patients in our series had long-term followup visits around 6 months. Follow-up dates were calculated from time of treatment until last follow-up. Images
were graded by both an attending dermatologist and radiation oncologist using the Radiation Therapy Oncology
Grading (RTOG) acute toxicity scale for skin from 0 to 5
based on cosmetic features. Cosmetic features include
erythema, dry or wet desquamation, ulceration, edema,
and decreased sweating at the site. Data values for toxicity
grades according to RTOG strata were reported as median
and range toxicity grades. Ranges were determined by
independent t-tests. Chi-square analysis was used to
determine the signiﬁcance of changes between different
follow-up dates and toxicity grading of patient lesions as
categorical variables.

Clinical outcome assessment
To assess clinical outcomes, electronic medical records
of all patients were searched for last follow-up with
clinical documentation by either the treating radiation
oncologist or referring dermatologist. In addition, all
available patients were contacted and interviewed by a

Figure 2 KC on the left nasal ala (top). KC treated using
Leipzig applicator and articulated arm device (bottom). Abbreviation: KC Z keratinocyte carcinoma.

radiation oncologist using telehealth to assess for recurrences. Telehealth was only used to assess for disease
recurrence and was not intended to grade toxicity. All
toxicity assessments were conducted at regular in-person
clinical appointments. Median follow-up for recurrence
was calculated from time of last HDR-BT until the patient
was contacted. In the event the patient was unable to be
contacted due to death, other illness, or other causes, the
last documentation in the electronic medical records by
the radiation oncologist or dermatologist was used for the
calculation.

Results
Between 2015 to 2018, 19 consecutive patients with a
total of 20 KCs were treated with HDR-BT at our institution and included for analysis. The median age of patients was 75.5 years (44-93). Of the patients, 16
presented with BCC, and 3 had SCC (Table 1). The most
common location of malignancy was the nose (12 KCs,
60%), followed by scalp (4 KCs, 20%), lip/labial fold
(2 KCs, 10%), temporal region (1 KC, 5%), and eyelid
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(1 KC, 5%) (Table 2). Moreover, 1 patient had KCs at
more than 1 location at presentation (5%). Of the lesions,
the most common subtype was nodular BCC (56%),
followed by SCC in situ (for additional details on subtype
please refer to Table 2). Median treatment dose was 42
Gy in 6 fractions. Median (standard deviation) treatment
duration in days was 18 (4), whereas median short-term
follow-up was 14 days (15), and 3-month follow-up
was 63 (24). If needed, the median time for 6-month
follow-up was 160 days (92). Of the 19 patients in the
series, 19 had clinical follow-up at 2 weeks, 19 had
clinical follow-up at 3 months, and 18 of 19 (95%) had
long-term follow-up at or around 6 months, with 5
patients requiring toxicity assessments to include photographs at 6 months due to unresolved toxicity at 3
months.
The median toxicity (range) reported immediately
posttreatment was RTOG grade 2 (1-2). At the end of
treatment, 85% of treated lesions (n Z 17) exhibited
RTOG grade 2 toxicity and 15% of treated lesions (n Z
3) had grade 1. No grade 3 toxicities were reported at the
end of treatment. The most common grade 2 toxicities
after treatment were moderate erythema or edema at the
lesion site (Fig 3). At short-term follow-up (2 weeks
posttreatment), 50% of treated KCs (n Z 10) had RTOG
grade 1 toxicity, and 25% of treated KCs (n Z 5) had
grade 2 toxicity. By 3-month follow-up, 70% of treated
KCs (n Z 14) had RTOG grade 0 toxicity, and the other
30% of KCs (n Z 6) had grade 1 toxicity. The most
common RTOG grade 1 toxicity at 3 months of follow-up
was due to faint erythema and dryness at the treatment
site. By 6 months, all patients (n Z 5) who had unresolved toxicity at 3 months had RTOG grade 0 toxicity
(n Z 18), with no visible scarring or lesion. One patient
did not have follow-up for postradiation toxicity and is
inconclusive. Given the lack of data for this patient at
long-term follow-up, our toxicity analysis reports on 18
patients at the ﬁnal toxicity assessment. The RTOG
toxicity grade distribution is presented in Figure 4. No
RTOG grade 3 toxicity was observed at any time in the
current study. With a median follow-up of 7.2 months
(range, 1.3-54.4 months), the local recurrence-free survival was 94.7%, with only a single recurrence in our
series.

Discussion
The incidence of KCs has been rising over the last
several decades, as has the percentage of patients treated
for these malignancies.21,22 As the population ages the
proportion of elderly patients with KCs will also increase,
as 80% of KCs occur in people over the age of 60.18
Given the aging population, it is estimated that the
number of KCs presenting to dermatologists could increase by 50%. Surgical approaches with either excision
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Table 1

Clinical and treatment characteristics

Number of patients with KC
BCC
SCC
Patient demographics
Age (years)
Sex
Male
Female
Location of malignancy
Nose
Eyelid
Scalp
Lips/labial fold
Temporal region
Multiple locations
Local recurrence
No
Yes
Sex
Male
Female
Location of malignancy
Nose
Eyelid
Scalp
Lips/labial fold
Temporal region
Multiple locations
Clinical follow-up for toxicity
2 wk
3 mo
6 mo
Local recurrence
No
Yes

n Z 19
17 (85%)
3 (20%)
75.5 (44-93)
8 (44%)
10 (56%)
12 (63%)
1 (5%)
4 (21%)
2 (11%)
1 (5%)
2 (11%)
19 (95%)
1 (5%)
8 (44%)
10 (56%)
12 (63%)
1 (5%)
4 (21%)
2 (11%)
1 (5%)
2 (11%)
19 patients (100%)
19 patients (100%)
18 patients (95%)
19 (95%)
1 (5%)

Abbreviations: BCC Z basal cell carcinoma; KC Z keratinocyte
carcinoma; SCC Z squamous cell carcinoma.

or Mohs micrographic surgery (MMS) are considered the
standard of care treatment for KCs. However, the
increasing proportion of elderly patients with multiple
medical comorbidities and advancements in radiation
delivery have led to the justiﬁcation for the increasing use
of HDR-BT.
HDR-BT is an effective and noninvasive alternative
for the treatment of KCs in settings where surgical excision may be limited by select patient factors. Further,
HDR-BT is a more convenient option for patients as it
requires fewer numbers of treatments compared with
traditional EBRT. Although hypofractionated regimens
consisting of 5 or 6 fractions are sometimes employed,
they are more commonly used for lesions <5 mm and are
not supported by the American Society of Radiation
Oncology guidelines.20,23 In addition to a lack of
consensus regarding hypofractionation regimens,
5-fraction courses are often avoided for lesions >5 mm

Advances in Radiation Oncology: MarchdApril 2021
Table 2
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Tumor location and subtype for all patients

Patient number

Age/sex

Type of skin cancer

Location

Subtype

1
2
3
4
5
6
7
8
9
10
11
12
13
14

86/M
88/M
58/F
75
70/F
80/M
74/F
52/F
51/F
67/F
76/M
91/M
44/F
77/M

SCC
BCC
BCC
SCC
BCC
SCC
BCC
BCC
BCC
BCC
BCC
BCC
BCC
BCC

15
16
17
18
19

92/F
93/M
92/M
62/F
60/F

BCC
BCC
BCC
BCC
BCC

Scalp
Scalp
Nose
Nose
Nose
Left superior parietal scalp
Nose
Left nasal sidewall
Left nasal ala
Nasolabial fold
Nasal supratip
Right inferior vermillion lip
Left upper nasal bridge
Right forehead,
Left nose
Left central parietal scalp
Left nasal ala
Right upper lip
Nasal tip
Left nose

In situ
Nodular
Nodular
In situ
Nodular
Focally pseudoglandular
Nodular
Nodular
Nodular
Nodular
Nodular
Nodular
Nodular
Nodular ulcerated
Ulcerated
Pigmented nodular
Nodular
Nodular
Nodular and ulcerated
Nodular

Abbreviations: BCC Z basal cell carcinoma; SCC Z squamous cell carcinoma.

given concerns for lower biological effective doses
compared with HDR-BT.20 However, a 5-fraction course
is supported by the National Comprehensive Cancer
Center Network guidelines for KCs <20 mm, and this
fractionation schedule may be used in certain clinical
scenarios.19 Further, recent studies have shown that HDRBT leads to better cosmesis and local tumor control
compared with EBRT.24,25 Moreover, the increasing evidence of the utility of HDR-BT for the treatment of KCs
has led to the development and publication of skin
brachytherapy recommendations by Groupe Européen de
Curiethérapie - European Society for Therapeutic Radiology and Oncology and Advisory Committee
on Radiation Oncology Practice.16 In addition to
providing treatment recommendations, the conclusion of
this report speciﬁes that brachytherapy (BT) is an efﬁcient
and well-tolerated treatment that offers excellent cosmesis
and low toxicity for patients with skin cancer. Further, the
report concludes that carefully tailored BT is a good
alternative, if not the treatment of choice for those lesions
that cannot be safely removed by surgery.
Although KCs have low metastatic potential, their
potential for local tissue destruction has been associated
with detriments in QOL if left untreated.26-28 Speciﬁcally,
in elderly populations, studies have demonstrated that
healthy skin leads to better mental and emotional health as
well as improvements in social engagement.17,29 Other
studies have found that, independent of age, QOL impairments are more pronounced in patients with tumors
located in exposed areas such as the face that may pose
signiﬁcant cosmetic challenges for surgical resection.3

In our single-institution series of patients treated with
HDR-BT, we report high rates of local control (95%) with
good to excellent cosmetic outcomes. Our patient population, with a median treated age of 75.5 years, serves as a
representative population of patients who are routinely
referred for noninvasive treatment strategies. As such, we
believe that our study can provide meaningful information
in counseling elderly patients regarding the outcomes and
potential immediate, acute, and subacute toxicities of radiation treatment with HDR-BT, should such an approach
be taken for their KCs.
A common criticism of HDR-BT compared with surgical approaches has been that radiation therapy offers
inferior local control. Series of surgical resection show
recurrence rates at 5 years <5% even in sensitive
areas.7,30,31 In our study, we demonstrate a local control
rate of 95% with a median follow-up of 7.2 months
(range, 1.3-54.3 months). During our study period, only 1
lesion treated with HDR-BT had a local recurrence. The
local control we report is in accordance with prior data
and reﬂects the high ﬁdelity and efﬁcacy of HDR-BT in
this patient population. Several studies have shown
excellent rates of local control that approach those reported in series of surgery in patients treated with radiation therapy alone. In a review, Delishaj and colleagues14
report a median local control rate of 97% in studies of
HDR-BT. Several studies included in this review show
local control rates between 95% to 100%.32,33 Other
studies report excellent outcomes at 1 year both in terms
of local control (96.2%) and cosmetic outcomes.8 In a
systematic review and meta-analysis published in Cancer,
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Figure 3 Toxicity course- top image of a treated KC at 2 weeks, 3 months, and 6 months post-treatment. Bottom image- treated KC at
2 weeks and 3 months post-treatment.

Figure 4 Lesion grading at different time intervals. Data are expressed in numbers representing patients at different intervals. One
patient was lost to follow-up at 6 months, so the ﬁnal toxicity assessment includes 19 treated lesions.

Lee and colleagues24 reported on cosmetic outcomes and
recurrence rates among 18,095 patients with KCs treated
with either conventional excision, MMS, EBRT, or BT.

In this report, the authors demonstrate 1-year recurrence
rates of 0.2% and 0.0% for MMS and BT, respectively.24
Although data are limited, HDR-BT seems to provide

Advances in Radiation Oncology: MarchdApril 2021

excellent long-term outcomes with respect to tumor control, and we have conﬁrmed this in our patient population.
Speciﬁcally, in older populations, surgical resection
has been associated with higher rates of wound complications and poor healing.34 In a series of 241 patients over
the age of 75 undergoing surgical resection for skin
cancer, 20% of treated patients had 1 or more signiﬁcant
surgical complications.35 In our study, with a median
patient age of 75 years, we demonstrated a 15% rate of
grade 2 toxicity at the completion of treatment. On further
follow-up, at 6 months we demonstrated a 0% rate of
toxicity as measured using the RTOG scale, thus
providing evidence that HDR-BT may be a desired option
or even superior in this population compared with more
invasive approaches.
Another common criticism of radiation therapy is the
paucity of data detailing the long-term cosmetic outcomes
in patients treated with HDR-BT. However, in a recently
published series, the authors reported excellent cosmetic
outcomes in 98% of patients treated with HDR-BT at 5
years.17 In a study by Gauden et al,32 the authors reported
that 88% of patients treated with HDR-BT had good or
excellent cosmetic outcomes, with a follow-up of 66
months. Additionally, in the systematic review by Lee
et al,24 the summary effect size for “good” cosmetic
outcomes was 81%, 74.6%, and 97.6% for conventional
excision, EBRT, and BT, respectively. The only study
included in this review reporting on cosmetic outcomes
for MMS reported a 96% rate of “good” cosmesis.
Another limiting factor in the use of HDR-BT for skin
lesions is the limitation of the Leipzig skin applicator. The
size of the applicator limits its use to similarly small lesions. In addition, the applicator requires treatment en
face to achieve appropriate dose distributions to ensure
tumor coverage. Given these limitations, it can sometimes
be difﬁcult to apply the skin applicator to areas of the face
where an en face technique is not achievable, as on the
bridge of the nose. However, with proper set-up and
meticulous planning, HDR-BT can still be applied safely
and effectively to many lesions on the face and scalp.
Long-term data are a known limiting factor of the RTOG
scale, as cosmesis recorded at 3 and 6 months of follow-up
may deteriorate over time, and extended follow-ups are
needed to better characterize changes over time. However,
given that most series of HDR-BT are in elderly patients
with multiple medical comorbidities who likely have underlying disease processes that lead to impaired wound
healing, the results on cosmetic outcomes reported in the
literature are reassuring. Further, with high-dose radiation
delivery, acute toxicities are often more exaggerated than
when using lower dose or traditionally fractionated external
beam radiation, and the acute toxicities we report also
provide evidence that HDR-BT in elderly patients is a safe
alternative to surgical resection. In our current analysis, as
well as in practice, we have noticed a favorable cosmetic
outcome in patients who opt for noninvasive treatment

HDR brachytherapy toxicity in skin carcinomas
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strategies in areas of cosmetic importance, such as the tip of
their nose (Fig 1).
To ensure high quality of care, it is important for
radiation oncologists, dermatologists, and geriatricians
to identify patients who are ideal candidates for HDRBT based on tumor characteristics, location, and patient
risk assessment. This should be balanced with other
approaches such as surgery and in the context of any
associated medical comorbidity and risk of surgery or
postoperative complications. Our study intended to
evaluate the immediate, acute, and subacute adverse
events of HDR-BT as well as local control for the
treatment of KCs in our clinical practice. Our results
indicate a promising outcome and indication for the use
of radiation in the treatment of KCs and provides
additional evidence and support for the continued use
of HDR-BT as an alternative to surgery in high-risk
populations or in patients who decline surgery for fear
of decreased cosmetic outcomes.
To further investigate, we plan to conduct a large
prospective study assessing the outcome of HDR-BT in
the treatment of KCs of the skin. Moreover, proper indications for enhanced cosmetic and functional outcomes
in certain anatomic sites, like the tip of the nose, helix of
the ear, or ﬁnger knuckles, will be studied and compared
with reported surgical results in the literature. The followup prospective study also aims to report the efﬁcacy and
recurrence rate over a 2-year period of HDR-BT versus
surgical treatment.
The current analysis has several strengths, including a
multidisciplinary treatment approach at a high volume
academic center for patients with KCs, a detailed followup posttreatment for cosmetic outcomes (using patient
photos), and a uniform and reproducible brachytherapy
procedure. Limitations of the current study include the
small sample size, the lack of long-term cosmetic and
oncologic outcomes, and the retrospective nature of the
study. However, despite these limitations, we believe our
study provides evidence of the role, safety, and efﬁcacy of
an HDR-BT approach for the treatment of KCs in a
predominantly elderly population.

Conclusions
HDR-BT demonstrates an expected course of toxicity
in patients being treated for KCs of appropriate type and
size with similar efﬁcacy to surgical excision during the
follow-up period and desired cosmetic results. A peak
RTOG grade 2 toxicity and cosmetic features including
dryness, erythema, and decreased sweating can be expected from the end of treatment to short-term follow-up.
The toxicity typically resolves within 3 months, and by 6
months, almost all toxicity resolves. As such, we
demonstrate the safety and efﬁcacy of HDR-BT for the
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treatment of KCs in sensitive areas among an elderly
population.
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